ClinicalTrials.gg
RecruitingNCT07441525Updated Mar 2, 2026

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

An Early Phase 1 interventional study of CART Infusion in Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenic Purpura and Evans Syndrome, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Anemia, Hemolytic, Autoimmune with a site in China — 22 open to participants now, 30 under way, 4 of them phase 3. Anemia, Hemolytic, Autoimmune · China.

Planned enrollment
14th of 35
27 · median 18
Started
2026
with 8 others
Phase 1
19 of 39
10 open now
Primary completion
2029-01
later than 26 of 29 live
Registered
30th of 39
by date
Lead sponsor
2 of 39
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Among the 39 studies in Anemia, Hemolytic, Autoimmune with a site in China, this one is the 14th largest by planned enrollment of the 35 interventional ones that give a count, is one of 9 that started in 2026, is one of 19 in phase 1, reaches primary completion later than 26 of the 29 other live ones, and was the 30th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

22 of the 39 studies in Anemia, Hemolytic, Autoimmune with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Anemia, Hemolytic, Autoimmune with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of RD06-05 in subjects with autoantibody-mediated autoimmune hematological diseases. The enrolled population consists of patients with active autoimmune hematological diseases, including primary immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), and Evans syndrome.

This study sets two dose groups: 6 × 10⁶ CAR⁺T cells/kg and 10 × 10⁶ CAR⁺T cells/kg, with the initial dose being 6 × 10⁶ CAR⁺T cells/kg. To reduce efficacy risks, the dose may be escalated to 10 × 10⁶ CAR⁺T cells/kg following evaluation and recommendation by the Safety Review Committee (SRC). The SRC's recommendation on dose escalation will be based on a comprehensive assessment of all available safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data.

03

Conditions studied

  • Autoimmune Hemolytic Anemia
  • Primary Immune Thrombocytopenic Purpura
  • Evans Syndrome

Keywords

  • UCART
  • CD19/BCMA
  • ITP
  • AIHA
  • EVANS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily participate in this trial and sign the form.
  • Aged ≥ 18 years and ≤ 75 years, regardless of gender.
  • Organ function and laboratory tests:

    1. Liver function: (ALT) and Aspartate Aminotransferase (AST) ≤ 3 × (ULN); Total (TBIL) ≤ 2 × ULN (except for Gilbert's Syndrome).
    2. Renal function: Creatinine ≤ 1.5 × ULN or Rate ≥ 40 ml/min.
    3. Oxygen saturation (SpO2) ≥ 92% in room air at rest.
    4. Echocardiography shows (LVEF) ≥ 50%.
  • Female subjects of must have a negative result in serum or urine pregnancy test at screening.
  • Female subjects of childbearing potential must agree to use highly effective methods from at least 28 days before the start of lymphodepletion to 12 months after reinfusion on RD06-05. Male subjects of childbearing potential must agree to use effective barrier contraceptive methods from the start of lymphodepletion to 12 months after reinfusion on RD06-05, and must not donate semen or sperm during the entire trial period.
  • Subjects with primary Immune Thrombocytopenia (ITP), with a disease duration of at least > 6 months.
  • or relapsed ITP: Subjects show no response, unsustained response, or intolerance to at least 2 different categories of standard treatments (e.g., , splenectomy, intravenous immunoglobulin (IVIg), thrombopoietin receptor agonists (TPO-RA), Bruton's tyrosine kinase (BTK) inhibitors, etc.); among which, subjects must have received at least one or more treatments from IVIg, TPO-RA, or BTK inhibitors. In addition, counts must be \< 30,000/μL in two tests conducted within 15 days before the start of study treatment, with an interval of at least 7 days between the two tests.
  • Complete blood count: ≥ 1,000/µL, ≥ 60g/L.
  • Subjects with Hemolytic Anemia (AIHA), including warm autoimmune hemolytic anemia (wAIHA), mixed autoimmune hemolytic anemia (mix-AIHA), and cold agglutinin disease (CAD), with a disease duration of at least > 6 months.
  • Refractory or relapsed AIHA: Subjects show no response, unsustained response, or intolerance to at least 3 (e.g., glucocorticoids, rituximab, , splenectomy, complement inhibitors, etc.).
  • Laboratory evidence of hemolysis: At least one of the following conditions exists in either the screening period or any test within the past 3 months: haptoglobin below the lower limit of normal, or total bilirubin (especially indirect bilirubin) above the upper limit of normal, or lactate dehydrogenase (LDH) above the upper limit of normal, and/or elevated reticulocyte count.
  • Complete blood count: Neutrophil count ≥ 1,000/µL, hemoglobin (Hb) \< 100g/L.
  • Diagnosed with Evans Syndrome (ES), with a disease duration of at least > 6 months.
  • Refractory or relapsed ES: After at least 3 lines of systemic treatments (e.g., glucocorticoids, intravenous immunoglobulin (IVIg), rituximab, immunosuppressants, splenectomy, thrombopoietin receptor agonists (TPO-RA), complement inhibitors, etc.), at least one type of cytopenia (thrombocytopenia or hemolytic anemia) still shows no response, unsustained response, or intolerance.
  • Laboratory evidence of active blood cell destruction: Platelet count \< 30,000/μL or manifestations of hemolysis exist during the screening period or within the past 3 months, such as haptoglobin \< lower limit of normal, or total bilirubin (especially indirect bilirubin) > upper limit of normal, or LDH > upper limit of normal, and/or elevated reticulocyte count.
  • Definite response to at least one previous treatment:

Platelet (PLT) treatment response: Platelet count reaches ≥ 50,000/μL in at least 2 tests, with an increase of ≥ 20,000/μL compared to the baseline.

Hemoglobin (Hb) treatment response: Hb increases by ≥ 10-15 g/L or hemolysis indicators improve.

Exclusion criteria

Exclusion Criteria:

  • Has a coexisting disease that may seriously interfere with the attribution of study disease activity or pose additional safety risks. However, if the subject's condition has been clinically stable for ≥ 3 months, and it is expected not to interfere with study assessments, the subject may be enrolled after confirmation by the investigator and approval by the sponsor's medical monitor (or their designee).
  • Has rapidly progressive glomerulonephritis (RPGN), defined as any of the following:

    • Renal shows crescent formation in ≥ 50% of glomeruli.
    • Sustained doubling of serum creatinine level within 2 months before screening.
    • The investigator assesses that the subject has RPGN.
  • Subjects with the following cardiac diseases will be excluded:

    • History of heart failure classified as (NYHA) Class III or IV.
    • History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious cardiac diseases within 12 months before enrollment.
  • Has a history of severe central nervous system (CNS) diseases that may affect the subject's ability to comply with the study protocol or interfere with the accuracy of study assessments, such as: traumatic brain injury, disturbance of consciousness, epilepsy, cerebral vascular ischemia, or cerebral vascular hemorrhage.
  • Has a history of malignant tumors other than cured non-melanoma skin cancer or carcinoma in situ (e.g., carcinoma in situ of the cervix, bladder, or breast), unless the subject has been disease-free for at least 3 years.
  • Primary immunodeficiency.
  • Has uncontrolled infection; simple urinary tract infections and upper respiratory tract infections are permitted as judged by the investigator and the sponsor's medical monitor (or their designee).
  • Has a known history of infection with (HIV), virus (HCV), or syphilis.
  • Active or latent virus (HBV) infection.
  • Positive results for Epstein-Barr virus (EBV) or cytomegalovirus (CMV) DNA or IgM antibodies during the screening period.
  • Has a history of recurrent tuberculosis or known recurrent tuberculosis.
  • Has a history of previous chimeric antigen receptor T-cell (CAR-T) therapy or any other genetically modified immune cell therapy.
  • Has received a within 4 weeks before enrollment.
  • Has a history of allergy to any component of the cell therapy product.
  • Has a history of to tacrolimus, or has experienced ≥ Grade 3 tacrolimus-related toxicity in the past (including but not limited to neurological, gastrointestinal, hepatic, renal, or hematological toxicity), especially subjects who required hospitalization will be excluded. Other cases may be considered eligible after confirmation by the investigator and the sponsor's medical monitor (or their designee).
  • Has participated in another clinical trial within 30 days before screening.
  • Pregnant or lactating subjects, as well as subjects of who cannot take effective measures.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    CART Treatment Group

    All participants will recevie CAR+T cells infusion with dose groups of 6 × 10⁶ CAR+T cells/kg and 10 × 10⁶ CAR+T cells/kg.

    Drug: CART Infusion

Interventions

  • DrugCART Infusion

    All participants will recevie CAR+T cells infusion with dose groups of 6 × 10⁶ CAR+T cells/kg and 10 × 10⁶ CAR+T cells/kg.

06

What researchers measure

Primary outcomes

  1. The incidence rates of Serious Adverse Events that occur during treatment

    Time frame: From the day of cell infusion to months 24 after cell infusion

  2. The incidence rates of Treatment-Emergent Adverse Events that occur during treatment

    Time frame: From the day of cell infusion to months 24 after infusion

  3. The incidence rates of Adverse Events of Special Interest that occur during treatment

    Time frame: From the day of cell infusion to months 24 after cell infusion

Secondary outcomes

  1. ITP: The proportion of subjects who achieve a sustained platelet response

    Time frame: From the day of cell infusion to months 24 after cell infusion

  2. ITP: Overall Response Rate (ORR)

    Time frame: From the day of cell infusion to months 24 after cell infusion

  3. ITP: Complete Response Rate (CR)

    Time frame: From the day of cell infusion to months 24 after cell infusion

  4. ITP: PartialResponse Rate (PR)

    Time frame: From the day of cell infusion to months 24 after cell infusion

  5. ITP: Duration of Sustained Platelet Response

    Time frame: From the day of cell infusion to months 24 after cell infusion

  6. ITP: Duration of Complete Response

    Time frame: From the day of cell infusion to months 24 after cell infusion

  7. AIAH: The proportion of subjects who achieve a durable hemoglobin response

    Time frame: From the day of cell infusion to months 24 after cell infusion

  8. AIAH: Overall Response Rate (ORR)

    Time frame: From the day of cell infusion to months 24 after cell infusion

  9. AIAH: Complete Response Rate (CR)

    Time frame: From the day of cell infusion to months 24 after cell infusion

  10. AIAH: PartialResponse Rate (PR)

    Time frame: From the day of cell infusion to months 24 after cell infusion

  11. AIAH: Complete Hematologic Response with CompensatedHemolysis (CRi)

    Time frame: From the day of cell infusion to months 24 after cell infusion

  12. AIAH: Duration of Response (DOR)

    Time frame: From the day of cell infusion to months 24 after cell infusion

  13. Evans Syndrome: CR: Shall include both AIHA-CR and ITP-CR.

    Time frame: From the day of cell infusion to months 24 after cell infusion

  14. Evans Syndrome: PR: AIHA/ITP (either) achieves CR/PR, or both achieve PR

    Time frame: From the day of cell infusion to months 24 after cell infusion

  15. EVANS Syndrome: Duration of response

    Time frame: From the day of cell infusion to months 24 after cell infusion

07

Study locations

1 of 1 sites recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, Hubei, China
    Recruiting
    • Wei Xie, Attending Physician · Contactsherryxw@163.com · 027-8572600
    • Heng Mei, Prof. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 2, 2026
StartActual
Feb 3, 2026
Primary completionEst.
Jan 10, 2029
CompletionEst.
Jun 30, 2029
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07441525
Collaborators
Nanjing Bioheng Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Feb 3, 2026
Primary completion
Jan 10, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Mar 2, 2026

Study contacts

Wei Xie, Attending Physician
Contact
sherryxw@163.com
027-8572600

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion